MDB-401B is under clinical development by Salspera and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MDB-401B’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MDB-401B is under development for the treatment of solid tumors, metastatic pancreatic adenocarcinoma. The drug candidate is administered through oral route. It is an genetically engineered salmonella expressing interleukin-2.
For a complete picture of MDB-401B’s drug-specific PTSR and LoA scores, buy the report here.